Bio-business in brief: a case for new drugs at generic prices from India

The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate p...

Full description

Saved in:
Bibliographic Details
Published in:Current science (Bangalore) 2012-05, Vol.102 (10), p.1375-1381
Main Authors: Venkatachalam, Suri, Saberwal, Gayatri
Format: Article
Language:English
Subjects:
Business structures
Complementary therapies
Drug discovery
Funding
GENERAL ARTICLES
Generic drugs
Health care industry
Molecules
Multilateralism
Nonprofit organizations
Philanthropy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1381
container_issue 10
container_start_page 1375
container_title Current science (Bangalore)
container_volume 102
creator Venkatachalam, Suri
Saberwal, Gayatri
description The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in India, it could lower the cost of innovation. Funding could be from a variety of players that expect a social, not financial, return. The drugs thus developed could be licensed out to a limited number of generic pharma companies, and thus be available at generic prices immediately.
format article
fullrecord <record><control><sourceid>jstor</sourceid><recordid>TN_cdi_jstor_primary_24107794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24107794</jstor_id><sourcerecordid>24107794</sourcerecordid><originalsourceid>FETCH-LOGICAL-j107t-65a816bf670037278003fc75c1cbbda210fbd1905b1c4f1aa3b17fb33686e6b3</originalsourceid><addsrcrecordid>eNotjsFKAzEUAHNQsFY_QXg_EHgv2U12vWlRWyj00nt5ySYli81KskX8exf0MnMb5kasEImk7nq6E_e1johKK-xXYvuaJumuNeVQK6QMrqQQn4HBcw0QpwI5fMNQrucKPMM55FCSh68FoUIs0wV2eUj8IG4jf9bw-O-1OL6_HTdbuT987DYvezkS2lmaljsyLhqLqK2y3aLobevJOzewIoxuoB5bR76JxKwd2ei0Np0Jxum1ePrLjnWeymnZuHD5Oalmqdu-0b_qXEOa</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bio-business in brief: a case for new drugs at generic prices from India</title><source>JSTOR</source><creator>Venkatachalam, Suri ; Saberwal, Gayatri</creator><creatorcontrib>Venkatachalam, Suri ; Saberwal, Gayatri</creatorcontrib><description>The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in India, it could lower the cost of innovation. Funding could be from a variety of players that expect a social, not financial, return. The drugs thus developed could be licensed out to a limited number of generic pharma companies, and thus be available at generic prices immediately.</description><identifier>ISSN: 0011-3891</identifier><language>eng</language><publisher>Current Science Association</publisher><subject>Business structures ; Complementary therapies ; Drug discovery ; Funding ; GENERAL ARTICLES ; Generic drugs ; Health care industry ; Molecules ; Multilateralism ; Nonprofit organizations ; Philanthropy</subject><ispartof>Current science (Bangalore), 2012-05, Vol.102 (10), p.1375-1381</ispartof><rights>2012 Current Science Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24107794$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24107794$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,58238,58471</link.rule.ids></links><search><creatorcontrib>Venkatachalam, Suri</creatorcontrib><creatorcontrib>Saberwal, Gayatri</creatorcontrib><title>Bio-business in brief: a case for new drugs at generic prices from India</title><title>Current science (Bangalore)</title><description>The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in India, it could lower the cost of innovation. Funding could be from a variety of players that expect a social, not financial, return. The drugs thus developed could be licensed out to a limited number of generic pharma companies, and thus be available at generic prices immediately.</description><subject>Business structures</subject><subject>Complementary therapies</subject><subject>Drug discovery</subject><subject>Funding</subject><subject>GENERAL ARTICLES</subject><subject>Generic drugs</subject><subject>Health care industry</subject><subject>Molecules</subject><subject>Multilateralism</subject><subject>Nonprofit organizations</subject><subject>Philanthropy</subject><issn>0011-3891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotjsFKAzEUAHNQsFY_QXg_EHgv2U12vWlRWyj00nt5ySYli81KskX8exf0MnMb5kasEImk7nq6E_e1johKK-xXYvuaJumuNeVQK6QMrqQQn4HBcw0QpwI5fMNQrucKPMM55FCSh68FoUIs0wV2eUj8IG4jf9bw-O-1OL6_HTdbuT987DYvezkS2lmaljsyLhqLqK2y3aLobevJOzewIoxuoB5bR76JxKwd2ei0Np0Jxum1ePrLjnWeymnZuHD5Oalmqdu-0b_qXEOa</recordid><startdate>20120525</startdate><enddate>20120525</enddate><creator>Venkatachalam, Suri</creator><creator>Saberwal, Gayatri</creator><general>Current Science Association</general><scope/></search><sort><creationdate>20120525</creationdate><title>Bio-business in brief: a case for new drugs at generic prices from India</title><author>Venkatachalam, Suri ; Saberwal, Gayatri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j107t-65a816bf670037278003fc75c1cbbda210fbd1905b1c4f1aa3b17fb33686e6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Business structures</topic><topic>Complementary therapies</topic><topic>Drug discovery</topic><topic>Funding</topic><topic>GENERAL ARTICLES</topic><topic>Generic drugs</topic><topic>Health care industry</topic><topic>Molecules</topic><topic>Multilateralism</topic><topic>Nonprofit organizations</topic><topic>Philanthropy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venkatachalam, Suri</creatorcontrib><creatorcontrib>Saberwal, Gayatri</creatorcontrib><jtitle>Current science (Bangalore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venkatachalam, Suri</au><au>Saberwal, Gayatri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bio-business in brief: a case for new drugs at generic prices from India</atitle><jtitle>Current science (Bangalore)</jtitle><date>2012-05-25</date><risdate>2012</risdate><volume>102</volume><issue>10</issue><spage>1375</spage><epage>1381</epage><pages>1375-1381</pages><issn>0011-3891</issn><abstract>The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in India, it could lower the cost of innovation. Funding could be from a variety of players that expect a social, not financial, return. The drugs thus developed could be licensed out to a limited number of generic pharma companies, and thus be available at generic prices immediately.</abstract><pub>Current Science Association</pub><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0011-3891
ispartof Current science (Bangalore), 2012-05, Vol.102 (10), p.1375-1381
issn 0011-3891
language eng
recordid cdi_jstor_primary_24107794
source JSTOR
subjects Business structures
Complementary therapies
Drug discovery
Funding
GENERAL ARTICLES
Generic drugs
Health care industry
Molecules
Multilateralism
Nonprofit organizations
Philanthropy
title Bio-business in brief: a case for new drugs at generic prices from India
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A08%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bio-business%20in%20brief:%20a%20case%20for%20new%20drugs%20at%20generic%20prices%20from%20India&rft.jtitle=Current%20science%20(Bangalore)&rft.au=Venkatachalam,%20Suri&rft.date=2012-05-25&rft.volume=102&rft.issue=10&rft.spage=1375&rft.epage=1381&rft.pages=1375-1381&rft.issn=0011-3891&rft_id=info:doi/&rft_dat=%3Cjstor%3E24107794%3C/jstor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j107t-65a816bf670037278003fc75c1cbbda210fbd1905b1c4f1aa3b17fb33686e6b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_jstor_id=24107794&rfr_iscdi=true